Please ensure Javascript is enabled for purposes of website accessibility

Why MacroGenics Stock Jumped 29% Today

By Todd Campbell – Updated May 11, 2020 at 4:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Optimism is growing ahead of the release of abstracts this week for the upcoming ASCO 2020 conference.

What happened

Shares of MacroGenics (MGNX 8.70%) surged today, ahead of the May 13 release of abstracts of presentations scheduled for the American Society of Clinical Oncology meeting at the end of the month. Investor optimism that the abstracts will reveal promising data for the company's early-stage drugs sent shares soaring 29.4% by the close on Monday.

So what

Margetuximab, an optimized formulation of the top-selling breast cancer drug Herceptin, is the biotech's most advanced drug. Last week, news that a Food and Drug Administration decision on margetuximab could happen by the end of 2020 sparked a one-day rally of over 200%. Today, the company's earlier-stage drug candidates, MGD013 and MGC018, are fueling optimism.

A person drawing an uptrending arrow on paper.

Image source: Getty Images.

MGD013 is an anti-Lag3 & PD-1 bispecific monoclonal antibody being evaluated in phase 1 trials in the treatment of metastatic breast cancer. At ASCO, researchers are expected to discuss a 40% overall response rate in HER2+ solid-tumor patients receiving a combination therapy of MGD013 and margetuximab.

Researchers are also expected to share insight into an MGC018 phase 1 trial in prostate cancer patients. Last week, MacroGenics said the anti-B7-H3 antibody drug conjugate reduced prostate-specific antigen, or PSA, by over 50% in five of seven patients with metastatic castration-resistant prostate cancer.

Now what

If there aren't any surprises in the abstracts, it could bolster the argument that MacroGenics is building out a multidrug platform of potential blockbuster medications. 

The company expects to report final data for overall survival for its phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer later this year. It also thinks it has a shot at receiving an FDA decision for the drug as soon as December. If approved, it could become a top-selling alternative to Herceptin, which had sales of over $6 billion in 2019 despite having already lost patent protection. Previously, margetuximab outpeformed Herceptin, producing a progression-free survival rate of 5.8 months versus 4.9 months for Herceptin. 

If magetuximab wins an OK and MGD013 combination therapy is effective, it could help the company reshape breast cancer treatment someday. Positive MGC018 data would similarly be good news because prostate cancer treatment is a multibillion-dollar market. Given the importance of the data in these upcoming abstracts, MacroGenics could be in store for more volatility this week, so only the most aggressive investors ought to consider buying it.


Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MacroGenics Stock Quote
$3.75 (8.70%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.